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TO THE EDITOR
Mutations in FLG, the gene encoding
profilaggrin/filaggrin, are the underlying
cause of ichthyosis vulgaris (OMIM
146700) and an important predi-
sposing factor for atopic eczema (AE)
(Sandilands et al., 2007). FLG muta-
tions are also significantly associated
with asthma with AE mainly in the
European population (Rodrı´guez et al.,
2009; van den Oord and Sheikh, 2010).
The presence of population-specific
FLG mutations has been reported in
both the European and Asian races
(Nomura et al., 2007; Sandilands
et al., 2007). To clarify whether FLG
mutations are a predisposing factor for
asthma in the non-European popula-
tion, we initially studied 172 Japanese
AE patients (mean age, 24.8±9.1 years)
and 134 unrelated Japanese control
individuals (healthy volunteers; mean
age, 27.9±6.0 years). All AE patients
had been diagnosed based on widely
recognized diagnostic criteria (Hanifin
and Rajka, 1980). The majority of AE
patients and control individuals were
identical to those in a previous study
(Nemoto-Hasebe et al., 2010). In this
AE cohort, 73 AE patients (mean age,
25.4±8.9 years) experienced compli-
cations with asthma. Furthermore, we
studied another Japanese asthma cohort
(137 patients; mean age, 58.2±16.9
years). Patients were considered asth-
matic based on the presence of recur-
rent episodes of Z2 of the three
symptoms (coughing, wheezing, or
dyspnea) associated with demonstrable
reversible airflow limitation, either
spontaneously or with an inhaled short-
acting b2-agonist and/or increased
airway responsiveness to methacholine
(Isada et al., 2010). Fully informed
consent was obtained from the partici-
pants or their legal guardians for this
study. This study had been approved by
the Ethical Committee at Hokkaido
University Graduate School of Medi-
cine and was conducted according to
the Declaration of Helsinki Principles.
FLG mutation screening revealed
that 27.4% of patients in our Japanese
AE complicated with asthma case
series carried one or more of the eight
FLG mutations (combined minor allele
frequency of 0.151, n¼ 146) (Table 1).
Conversely, 26.3% of Japanese AE
patients without asthma carried one or
more of the eight FLG mutations
(combined minor allele frequency of
0.147, n¼198). The FLG variants are
also carried by 3.7% of Japanese con-
trol individuals (combined minor allele
frequency of 0.019, n¼ 268). We found
that all compound heterozygous muta-
tions were present in trans by observing
transmission or haplotype analysis
(Nomura et al., 2007, 2008). There is
a statistically significant association
between the eight FLG mutations and
AE with asthma, and between the eight
FLG mutations and AE without asthma
(Table 1). Moreover, AE complicated
with asthma manifested in heterozy-
gous carriers of FLG mutations with an
odds ratio for AE and asthma of 9.74
(95% confidence interval 3.47–27.32),
suggesting a relationship between
FLG mutations and AE with asthma.
In the Japanese general asthma
cohort, 8.0% of the asthma patients
carried one or more of the eight FLG
mutations (combined minor allele fre-
quency of 0.04, n¼ 274) (Table 2).
Whereas, of the Japanese patients with
asthma complicated by AE, 22.2%
carried one or more of the FLG muta-
tions (combined minor allele frequency
of 0.11, n¼36). In contrast, 5.9% of
asthma patients without AE carried
one or more of the FLG mutations
(combined minor allele frequency of
0.03, n¼238). There was a statistically
significant association between the
eight FLG mutations and asthma with
AE (Table 2). There was no statistically
significant association between the FLG
mutations and entire asthma patients,
nor between FLG mutations and asthma
without AE. We cannot exclude the
possibility that this lack of significant
association is due to the small number
of the patients included in this study.
We used the same control set for both
case-controlled studies. Thus, strictly
speaking, there is no independent
replication for the control group.
Recent meta-analysis revealed that
FLG mutations are significantly asso-
ciated with asthma in the European
population and there are especially,
strong effects observed for FLG muta-
tions for the compound phenotype,
asthma in addition to eczema (Rodrı´-
guez et al., 2009; van den Oord and
Sheikh, 2010). In contrast, there
appeared to be no association of FLG
mutations with asthma in the absence
of eczema (Rodrı´guez et al., 2009; van
den Oord and Sheikh, 2010).
This Japanese cohort has a comple-
tely different FLG mutation spectrum
from those in the European and the
North American populations. However,
our results clearly confirm the strong
association of FLG mutations with our
Japanese cohort of AE patients with
asthma complications, and the associa-
tion of FLG mutations and asthma
patients with AE complications, for the
first time outside Europe or North
America. Conversely, this study showed
no significant correlation between gen-
eral asthma patients and FLG muta-
tions, suggesting that atopic asthma
patients associated with FLG mutations
are a minority among general asthma
patients. The frequency of heterozy-
gous, compound heterozygous, and
homozygous FLG mutation carriersAbbreviation: AE, atopic eczema
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observed in our Japanese controls was
only 3.7%, which was much lower than
that seen in European general popula-
tion, where it is approximately 7.5%.
This suggested that there may be further
mutations yet to be discovered in the
Japanese. As we have sequenced more
than 40 Japanese families with ichthyo-
sis vulgaris, there is now little possibi-
lity that further highly prevalent
mutations will be found in the Japanese
population. However, it is still possible
that there might be multiple, further
low-frequency FLG mutations discov-
ered in the Japanese population.
In addition, because of the relatively
small sample size of this genetic study,
further replication in association studies
will be required for FLG mutations and
asthma in Japan.
In our cohorts, serum IgE levels were
extremely high (median, 3141.9 IU ml1;
25th–75th percentiles, 1276.0–9753.
0 IUml1) in AE patients with asthma
(n¼73) in the AE cohort, compared with
that in total asthma patients (median,
156.0 IUml1; 25th–75th percentiles,
71.05–441.45 IU ml1, n¼ 137) in the
asthma cohort. These findings suggest
that extrinsic allergic sensitization might
have an important role in atopic asthma
pathogenesis. Recent studies hypothe-
sized skin barrier defects caused by FLG
mutation(s) allow allergens to penetrate
the skin, resulting in initiation of further
immune response and leading to the
development of systemic allergies, includ-
ing atopic asthma (Fallon et al., 2009). In
patients with asthma that also harbor FLG
mutations, we could not exclude the
possibility that the systemic effects of early
eczema might simply influence airway
responsiveness (Henderson et al., 2008).
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Table 1. Atopic eczema case–control association analysis for FLG null variants in Japan
R501X 3321delA S1695X Q1701X S2554X S2889X S3296X K4022X Combined
Genotype Con AE Con AE Con AE Con AE Con AE Con AE Con AE Con AE Con
AE
(total)
AE
(asthma+)
AE
(asthma)
AA 134 172 133 163 133 172 134 169 133 162 132 152 134 166 134 169 129 126 53 73
Aa 0 0 1 9 1 0 0 3 1 10 2 20 0 6 0 3 5 41 18 23
aa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 51 2 3
Total 134 172 134 172 134 172 134 172 134 172 134 172 134 172 134 172 134 172 73 99
Abbreviations: AE, atopic eczema; CI, confidence interval; Con, healthy control; OR, odds ratio.
For combined genotype: AE+asthma, exact P-value of Pearson w2-test=1.909 106, OR and 95% CI for dominant models (AA vs aX)=9.737 (3.473–27.322);
AEasthma, exact P-value of Pearson w2-test=7.189 107, OR and 95% CI for dominant models (AA vs aX)=9.191 (3.383–24.938); all AE, exact P-value of
Pearson w2-test=1.189107, OR and 95% CI for dominant models (AA vs aX)=9.416 (3.625–24.450).
1All the five patients were compound heterozygotes for minor alleles.
Table 2. Asthma case–control association analysis for FLG null variants in Japan
R501X 3321delA S1695X Q1701X S2554X S2889X S3296X K4022X Combined
Genotype Con Asthma Con Asthma Con Asthma Con Asthma Con Asthma Con Asthma Con Asthma Con Asthma Con
Asthma
(total)
Asthma
(AE+)
Asthma
(AE)
AA 134 137 133 137 133 137 134 137 133 133 132 132 134 136 134 136 129 126 14 112
Aa 0 0 1 0 1 0 0 0 1 4 2 5 0 1 0 1 5 11 4 7
aa 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 134 137 134 137 134 137 134 137 134 137 134 137 134 137 134 137 134 137 18 119
Abbreviations: AE, atopic eczema; CI, confidence interval; Con, healthy control; OR, odds ratio.
For combined genotype: asthma+AE, exact P-value of Pearson w2-test=0.0122, OR and 95% CI for dominant models (AA vs aX)=7.3692 (1.7715–30.6748);
asthmaAE, exact P-value of Pearson w2-test=0.5563, OR and 95% CI for dominant models (AA vs aX)=1.6124 (0.4979–5.2219); all asthma, exact P-value of
Pearson w2-test=0.1968, OR and 95% CI for dominant models (AA vs aX)=2.2523 (0.7609–6.6667).
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RNase 7 Protects Healthy Skin from Staphylococcus aureus
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TO THE EDITOR
The Gram-positive bacterium Staphylo-
coccus aureus is an important pathogen
that causes various skin infections
(Miller and Kaplan, 2009). However,
healthy skin is usually not infected by
S. aureus, despite the high carrier rates
in the normal population (Noble,
1998). This suggests that the cutaneous
defense system has the capacity to
effectively control the growth of S.
aureus. There is increasing evidence
that antimicrobial proteins are impor-
tant effectors of the cutaneous defense
system (Harder et al., 2007). A recent
study reported that keratinocytes con-
tribute to cutaneous innate defense
against S. aureus through the produc-
tion of human b-defensin-3 (Kisich
et al., 2007). In addition to human b-
defensin-3,, other antimicrobial pro-
teins may also participate in cutaneous
defense against S. aureus. One candi-
date is RNase 7, a potent antimicrobial
ribonuclease that is highly expressed in
healthy skin (Harder and Schro¨der,
2002; Ko¨ten et al., 2009).
To investigate the hypothesis that
RNase 7 may contribute to protect
healthy skin from S. aureus coloniza-
tion, we first incubated natural RNase 7
isolated from stratum corneum skin
extracts (Harder and Schro¨der, 2002)
with S. aureus (ATCC 6538). In con-
cordance with our initial report about
RNase 7 (Harder and Schro¨der, 2002),
we verified that RNase 7 exhibited
a high killing activity against S. aureus
(lethal dose of 90% ¼3–6 mg ml1).
Recently, we reported a moderate
induction of RNase 7 mRNA expres-
sion in primary keratinocytes treated
with heat-killed S. aureus (Harder and
Schro¨der, 2002). To assess the induc-
tion of RNase 7 by S. aureus in the
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Figure 1. Induced secretion of RNase 7 on the skin surface on treatment with living S. aureus.
Defined areas (0.8 cm2) of skin explants derived from plastic surgery were incubated with or without
approximately 1,000 colony-forming units of S. aureus (ATCC 6538) in 100 ml of sodium phosphate
buffer. After 2, 6, and 20 hours, the concentration of secreted RNase 7 was determined by ELISA.
Stimulation with S. aureus for 2 hours revealed a significant induction as compared with the
unstimulated control after 2 hours (*Po0.05, Student’s t-test; n.s.¼ not significant). Data shown are
means of triplicates of five skin explants derived from five donors.
See related commentary on pg 2703
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